Will it be good for RCPIQ shareholders?
No one who posts on this board knows the answer to that question, but I did address that question in post #27884. Should Nilvadipine turn out to be at least a modest breakthrough in the effort to stop Alzheimer's in its tracks, it would make Roskamp the center of worldwide attention. Dr. Mullan is in charge, under the NILVAD STUDY, to bring an Alzheimer's supressing medication to market, and most here believe that anatabine can help in that effort.
At the very least, success with Nilvad should at least bring increased attention to anatabine as a safe anti-inflammatory.
